In a randomized trial of 46 high-risk cardiovascular patients, semaglutide increased vascular regenerative progenitor cells by 35% and endothelial precursors by 66% while reducing pro-inflammatory granulocyte precursors by 51%, suggesting a new mechanism for cardiovascular protection.
+66% endothelial precursorsSemaglutide dramatically increased blood vessel repair progenitor cells while halving inflammatory granulocyte precursors in cardiovascular-risk patients
What the researchers found
Semaglutide increased VR cells +34.8% (vs +0.8% usual care, p=0.036), endothelial precursors +66.2% (vs -2.3%, p=0.037), and reduced granulocyte precursors -50.8% (vs +0.3%, p=0.002). Pro-inflammatory TNF and interleukin serum proteins were also downregulated.
Why it matters
This reveals a previously unknown mechanism by which GLP-1 drugs protect the cardiovascular system—by enhancing the body's natural blood vessel repair capacity through stem and progenitor cell mobilization while suppressing inflammatory cells that damage blood vessels.
The numbers in context
46 participants (22 semaglutide, 24 usual care). 6-month treatment. VR cells (ALDHhi SSClow) increased 34.8% with semaglutide vs 0.8% with usual care (P = 0.036). Myeloid progenitors up 40.1% vs 2.8% (P = 0.017). Endothelial precursors up 66.2% vs down 2.3%.
How the study worked
Randomized translational trial (SEMA-VR CardioLink-15) of 46 participants with T2D/obesity plus ASCVD or ASCVD risk factors. 22 received semaglutide, 24 usual care for 6 months. Multi-parametric flow cytometry for VR cell enumeration.
Who was studied
Adults with T2D and/or obesity plus atherosclerotic cardiovascular disease or risk factors
What this study cannot tell us
Small sample size (n=46). Open-label design (not blinded). Translational trial measuring surrogate cell markers, not clinical cardiovascular events. Six-month duration may not capture long-term effects. Mechanistic connection between VR cell increases and clinical outcomes is inferential.
How to read the evidence
Randomized translational trial with appropriate control group and rigorous flow cytometry methodology. Small sample but well-designed for a mechanistic study. Novel finding requiring replication.
When this study was published
Published in 2025; first randomized trial demonstrating semaglutide effects on vascular regenerative progenitor cells.
The bigger picture
GLP-1 drugs reduce cardiovascular events in clinical trials, but the mechanisms beyond glucose and weight control remain incompletely understood. This trial provides evidence that semaglutide actively reprograms the bone marrow's output toward regenerative and anti-inflammatory cell populations—a fundamentally new way to understand how peptide drugs protect blood vessels.
Questions still open
- Do the VR cell increases observed translate into measurable improvements in vascular repair and atherosclerosis regression?
- Is this progenitor cell mobilization effect unique to semaglutide or shared by all GLP-1 agonists?
- Could monitoring VR cell levels serve as a biomarker for cardiovascular benefit of GLP-1 therapy?
Common questions
How does semaglutide help repair blood vessels?
Is this why GLP-1 drugs reduce heart attacks and strokes?
Read the original research
Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.
European heart journal
Citation
Park, Brady; Dennis, Fallon; He, Arianna Z; Krishnaraj, Aishwarya; Bakbak, Ehab; Dennis, Cole J; Pan, Yi; Misner, Elizabeth; Thayanithy, Veena; Lambotharan, Bhavaani; Lambotharan, Vaasudevan; Lambotharan, Aruna; Mazer, C David; Quan, Adrian; Teoh, Hwee; Hess, David A; Verma, Subodh. (2025). Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.. European heart journal. https://doi.org/10.1093/eurheartj/ehaf690